Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply

Bruce E. Sands, Stefan Schreiber, Richard A. Lirio

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)93-94
Number of pages2
JournalNew England Journal of Medicine
Volume382
Issue number1
DOIs
StatePublished - 2 Jan 2020

Cite this